Doctor of Osteopathy Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Fredrick Munzer

Geriatric Medicine Johnstown, PA Doctor of Osteopathy

NPI 1063497584 CMS profile 139445

411 Theatre Dr, Johnstown, PA 15904

Open in the dashboard

General payments

$2,354

150 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Fredrick Munzer of Johnstown, PA is reported in the CMS Open Payments database as having received $2,354 across 150 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $54 3
2022 General $384 25
2021 General $781 55
2020 General $440 16
2019 General $694 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fredrick Munzer
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Fredrick Munzer were reported at $0. Among 512 Geriatric Medicine profiles paid that year, the median was $120 and the middle half received between $37 and $350.

Show as a table
Year Fredrick Munzer Geriatric Medicine median Middle half National median
2019 $694 $96 $28–$339 $163
2020 $440 $99 $28–$262 $114
2021 $781 $94 $27–$318 $132
2022 $384 $103 $34–$338 $149
2023 $54 $109 $39–$320 $160
2024 $0 $125 $36–$371 $164
2025 $0 $120 $37–$350 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $610 30 payments
  2. Novo Nordisk Inc $337 34 payments
  3. E.R. Squibb & Sons, L.L.C. $224 15 payments
  4. Pfizer Inc. $183 17 payments
  5. Allergan Inc. $138 3 payments
  6. Lilly USA, LLC $137 10 payments
  7. Sanofi-Aventis U.S. LLC $136 4 payments
  8. Janssen Pharmaceuticals, Inc $101 8 payments
  9. Amarin Pharma Inc. $74 1 payment
  10. AbbVie, Inc. $68 4 payments
  11. Other $344 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,348 149 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2023
  1. FARXIGA $558 26 payments
  2. ELIQUIS Cardiovascular $224 15 payments
  3. Ozempic $189 19 payments
  4. ELIQUIS Cardiovascular;Metabolic Disease $130 12 payments
  5. UBRELVY $126 2 payments
  6. RYBELSUS $123 11 payments
  7. JARDIANCE $111 8 payments
  8. TRULICITY $111 8 payments
  9. XARELTO $101 8 payments
  10. BRILINTA $100 4 payments
  11. Other $1,310 91 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

139

Median for Family Medicine: 130

Drug cost

$19,596

Median for Family Medicine: $5,773

Branded share of claims

38.1%

Median for Family Medicine: 16%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 17 $11,716
Rhopressa Netarsudil Mesylate Brand 12 $3,591
Vyzulta Latanoprostene Bunod Brand 12 $2,827
Atorvastatin Calcium Generic 36 $630
Pantoprazole Sodium Generic 14 $271
Metoprolol Succinate Generic 14 $247
Allopurinol Generic 11 $138
Clopidogrel Clopidogrel Bisulfate Brand 12 $125
Hydrochlorothiazide Generic 11 $50

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 699 Part D prescribers listed as Family Medicine; they describe a distribution and say nothing about conduct.

Records

150 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record